
-
Adverum Biotechnologies Inc. NasdaqCM:ADVM Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Location: 100 Cardinal Way, Redwood City, CA, 94063, United States | Website: https://adverum.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
57.31M
Cash
83.08M
Avg Qtr Burn
-28.0M
Short % of Float
12.91%
Insider Ownership
13.10%
Institutional Own.
79.48%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Phase 3 Data readout | |
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |